Enzyre B.V.

https://www.enzyre.com

Enzyre is a spin-out from Radboud University Medical Center in The Netherlands founded by Waander van Heerde and Guido Maertens. The Company aims to develop a diagnostic device to provide patients with the flexibility to assess their coagulation status regardless of where they are. Enzyre’s platform requires a small volume of blood to measure up to sixteen reactions simultaneously with high sensitivity and specificity without any laboratory infrastructure, at home, on the road or in a critical care setting. This offers enormous benefits to patients: avoid crisis situations driven by changes in coagulation status, provide ease of mind for patients, empower patients to optimize treatment themselves, be a quick turnaround tool in the clinical setting, reduce GP consultation visits and, as a personalized diagnostic tool, offer great support in a telemedicine setting *

	Start	2016-01-01 established
	Predecessor	Radboud University Medical Centre Nijmegen (RUMC)
	Industry	point-of-care diagnostic device
	Industry 2	biochip product (array, bead, lab-on-a-chip)
	Person	Pollet, Dirk (Enzyre 201904– CEO before Multiplicom + Cellectis + Galapagos + Innogenetics + Glaxo Wellcome)
	Person 2	Maertens, Guido (Enzyre 201904 CFO + Co-Founder)

	Region	Nijmegen
	Country	Netherlands
	Street	5 Transistorweg
	City	6534 AT Nijmegen
	Tel	+31-24-6690036
		Address record changed: 2020-12-02

Basic data	Employees	n. a.

		* Document for »About Section«: Enzyre B.V.. (11/2/22). "Press Release: Enzyre Closes Series A Financing Round of EUR 12M to Advance Pioneering Diagnostic Technology Platform for Hemophilia Patients". Nijmegen.

		Record changed: 2024-02-12